Thomas Englese - 08 Mar 2023 Form 4 Insider Report for AZIYO BIOLOGICS, INC. (ELUT)

Role: CHIEF COMMERCIAL OFFICER
Signature: /s/ Jeffrey Hamet, Attorney-in-Fact for Thomas Englese
Issuer symbol: ELUT
Transactions as of: 08 Mar 2023
Net transactions value: -$1,243
Form type: 4
Filing time: 09 Mar 2023, 20:18:07 UTC
Previous filing: 12 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELUT	Class A Common Stock	Options Exercise	$0	+937	+5.4%	$0.000000	18,206	08 Mar 2023	Direct	F1
transaction	ELUT	Class A Common Stock	Sale	$1,243	-289	-1.6%	$4.30	17,917	09 Mar 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELUT	Restricted Stock Units	Options Exercise	$0	-937	-33%	$0.000000	1,875	08 Mar 2023	Class A Common Stock	937		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of the restricted stock units ("RSUs").
F2	Represents shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
F3	On March 8, 2021, the Reporting Person was granted 3,750 RSUs, vesting in four substantially equal annual installments beginning on March 8, 2022.